Peconic Partners LLC Invests $342,000 in Pfizer, Inc. (NYSE:PFE)
Peconic Partners LLC acquired a new position in shares of Pfizer, Inc. (NYSE:PFE) during the first quarter, Holdings Channel reports. The fund acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $342,000.
Other large investors have also recently modified their holdings of the company. D Orazio & Associates Inc. boosted its stake in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 28 shares in the last quarter. Stone House Investment Management LLC boosted its stake in shares of Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 66 shares in the last quarter. Naples Global Advisors LLC boosted its stake in shares of Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 79 shares in the last quarter. Pure Financial Advisors Inc. boosted its stake in shares of Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock worth $756,000 after buying an additional 84 shares in the last quarter. Finally, Alpha Windward LLC boosted its stake in shares of Pfizer by 1.1% in the first quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock worth $287,000 after buying an additional 89 shares in the last quarter. Institutional investors own 70.10% of the company’s stock.
Pfizer, Inc. (PFE) traded down 0.51% during mid-day trading on Friday, reaching $33.25. The company’s stock had a trading volume of 12,928,473 shares. The firm has a 50 day moving average price of $33.40 and a 200-day moving average price of $33.31. The company has a market capitalization of $198.43 billion, a PE ratio of 24.32 and a beta of 1.00. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.38.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The company had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the firm earned $0.64 EPS. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, equities analysts predict that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.85%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
WARNING: This piece was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/12/peconic-partners-llc-invests-342000-in-pfizer-inc-nysepfe.html.
PFE has been the topic of a number of recent research reports. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the company a “neutral” rating in a report on Wednesday, August 2nd. Morgan Stanley reissued a “neutral” rating and issued a $35.00 target price (down previously from $38.00) on shares of Pfizer in a report on Monday, June 12th. Berenberg Bank set a $39.00 target price on Pfizer and gave the company a “neutral” rating in a report on Tuesday, August 1st. Citigroup Inc. lowered Pfizer from a “neutral” rating to a “sell” rating and dropped their target price for the company from $38.00 to $31.00 in a report on Tuesday, May 16th. Finally, BMO Capital Markets reissued a “hold” rating and issued a $33.00 target price on shares of Pfizer in a report on Thursday, April 27th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $37.77.
In related news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.